Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.72 |
| ▸ | RAB9A | P51151 | 7/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.66 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.66 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2289115 | 0.84 | NPC1 (1.00) | NPC1RAB9AKDM4ENOTUMTSHR | |
| SCHEMBL28671885 | 0.83 | NPC1 (0.79) | NPC1RAB9AKDM4ENOTUMDGAT1 | |
| SCHEMBL5754354 | 0.80 | KDM4E (0.71) | NPC1RAB9AKDM4ENOTUMDGAT1 | |
| SCHEMBL10112953 | 0.79 | KDM4E (0.66) | NPC1RAB9AKDM4ENOTUMDGAT1 | |
| SCHEMBL12550898 | 0.79 | KDM4E (0.66) | NPC1RAB9AKDM4ENOTUMDGAT1 | |
| SCHEMBL6903361 | 0.79 | KDM4E (1.00) | NPC1RAB9AKDM4ENOTUMDGAT1 | |
| SCHEMBL1143348 | 0.79 | KDM4E (1.00) | NPC1RAB9AKDM4ENOTUMDGAT1 | |
| SCHEMBL15718167 | 0.79 | DGAT1 (1.00) | NPC1RAB9AKDM4ENOTUMDGAT1 | |
| SCHEMBL15495513 | 0.79 | KDM4E (0.59) | NPC1RAB9AKDM4ENOTUMDGAT1 | |
| SCHEMBL3979 | 0.78 | NOTUM (1.00) | NPC1RAB9AKDM4ENOTUMDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346588-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | KUDA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4531838-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | Kuda Therapeutics, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-3672946-B1 | METABOLICALLY STABLE N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS | MICROBIOTIX INC (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023234970-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | KUDA Therapeutics, Inc. (US) | 2023-12-07 | — | — | WO | disclosed |
| US-20230109833-A1 | METABOLICALLY STABLE N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS | MICROBIOTIX, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-11505533-B2 | Metabolically stable N-acylaminooxadiazoles useful as antibacterial agents | MICROBIOTIX, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-11447482-B1 | Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis | KUDA Therapeutics, Inc. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220281862-A1 | Imidazopyridine and Oxazolopyridine Derivatives and Analogs Thereof, Methods of Preparation Thereof, Methods of HIF-2A Pathway Inhibition, and Induction of Ferroptosis | KUDA Therapeutics, Inc. | 2022-09-08 | — | — | US | disclosed |
| US-20220281862-A1 | Imidazopyridine and Oxazolopyridine Derivatives and Analogs Thereof, Methods of Preparation Thereof, Methods of HIF-2A Pathway Inhibition, and Induction of Ferroptosis | KUDA Therapeutics, Inc. | 2022-09-08 | — | — | US | disclosed |
| CN-110878106-B | Preparation method of Mannich base containing ferrocenyl thiadiazole or oxadiazolyl | 陕西科技大学 | 2022-05-03 | — | — | CN | disclosed |
| US-20200361882-A1 | METABOLICALLY STABLE N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS | MICROBIOTIX, INC. (US) | 2020-11-19 | — | — | US | disclosed |
| CN-111511723-A | Metabolically stable N-acylamino oxadiazoles as antibacterial agents | 米可如比奥提克斯有限公司 | 2020-08-07 | — | — | CN | disclosed |
| EP-3672946-A1 | METABOLICALLY STABLE N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS | Microbiotix, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| CN-110878106-A | Preparation method of Mannich base containing ferrocenyl thiadiazole or oxadiazolyl | 陕西科技大学 | 2020-03-13 | — | — | CN | disclosed |
| CN-107216357-B | Preparation method of Mannich base containing ferrocenyl oxadiazolyl | 陕西科技大学 | 2020-02-21 | — | — | CN | disclosed |
| CN-110759955-A | Preparation method of Mannich base containing ferrocenyl thiadiazole or oxadiazolyl | 陕西科技大学 | 2020-02-07 | — | — | CN | disclosed |
| WO-2019040404-A1 | METABOLICALLY STABLE N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS | MICROBIOTIX, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040404-A1 | METABOLICALLY STABLE N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS | MICROBIOTIX, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| CN-103980222-A | 2-amido-5-substituted-1,3,4-oxadiazole as well as preparation method and application thereof | UNIV SHAANXI SCIENCE & TECH | 2014-08-13 | — | — | CN | disclosed |
| CN-1126208-A | 2-amido-5-aryl-1,3,4-oxdiazole compound, its synthesis and application | HUADONG SCIENCE & ENGINEERING (CN) | 1996-07-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11505533-B2 | Metabolically stable N-acylaminooxadiazoles useful as antibacterial agents | RIOX2, MRPS35, AADAC | NPC1 2261/4885RAB9A 1031/4885KDM4E 3350/4885 |
| US-20200361882-A1 | METABOLICALLY STABLE N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS | RIOX2, MRPS35, AADAC | NPC1 2261/4885RAB9A 1031/4885KDM4E 3350/4885 |
| US-20250346588-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | HIF1AN, HIF1A, EGLN2 | NPC1 1895/4885RAB9A 3536/4885KDM4E 1020/4885 |
| US-11447482-B1 | Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of HIF-2A pathway inhibition, and induction of ferroptosis | HIF1AN, HIF1A, EGLN2 | NPC1 2512/4885RAB9A 3136/4885KDM4E 686/4885 |
| US-20220281862-A1 | Imidazopyridine and Oxazolopyridine Derivatives and Analogs Thereof, Methods of Preparation Thereof, Methods of HIF-2A Pathway Inhibition, and Induction of Ferroptosis | HIF1AN, HIF1A, EGLN2 | NPC1 2512/4885RAB9A 3136/4885KDM4E 686/4885 |
| US-20230109833-A1 | METABOLICALLY STABLE N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS | RIOX2, MRPS35, AADAC | NPC1 2261/4885RAB9A 1031/4885KDM4E 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.